Black Diamond Therapeutics Inc (BDTX) Reports Q4 and Full Year 2023 Financials, Advances ...

Mar 14, 2024 View Original Article
  • Bias Rating

    10% Center

  • Reliability

    25% ReliablePoor

  • Policy Leaning

    10% Center

  • Politician Portrayal

    N/A

Bias Score Analysis

The A.I. bias rating includes policy and politician portrayal leanings based on the author’s tone found in the article using machine learning. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral.

Sentiments

Overall Sentiment

20% Positive

  •   Liberal
  •   Conservative
SentenceSentimentBias
Unlock this feature by upgrading to the Pro plan.

Bias Meter

Extremely
Liberal

Very
Liberal

Moderately
Liberal

Somewhat Liberal

Center

Somewhat Conservative

Moderately
Conservative

Very
Conservative

Extremely
Conservative

-100%
Liberal

100%
Conservative

Bias Meter

Contributing sentiments towards policy:

51% : Its pipeline technology platform, Mutation-Allostery-Pharmacology, is targeting mutations in cancer, with drugs such as BDTX-4933 and BDTX-1535 under development.
40% : The company has recently dosed the first patient in a Phase 2 trial of BDTX-1535 for non-classical EGFRm NSCLC and is on track to present clinical data in the third quarter of 2024 for this trial.

*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.

Copy link